Metodebevisregister

Dose-Escalation Design

Dose-Escalation Design, formalized as the Continual Reassessment Method (CRM), is a Bayesian adaptive algorithm for identifying the Maximum Tolerated Dose (MTD) in Phase I clinical trials. Introduced by John O'Quigley, Margaret Pepe, and Lloyd Fisher in 1990, CRM treats dose-toxicity response as a parametric curve, updates a prior probability model after each patient's outcome, and assigns subsequent patients to the dose currently estimated closest to a pre-specified target toxicity probability.

Sources recorded, not reviewed

Kilderegister

Siteringer kopiert ordrett fra metodens kilderegister. Ingen påstandsnivåverifisering er underforstått fra dem.

Dose-Escalation Design (Continual Reassessment Method)

Taksonomisk metoderegister · process-pipeline / experimental-design

O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. · DOI 10.2307/2531628

Åpne full metode

Kuraterte påstander

Påstander lagret i bevishovedboken, hver med sin egen vurdering.

Ingen kuraterte påstander ennå

Denne visningen finner ikke opp en påstandsvurdering når hovedboken ikke har noen.

Relaterte metoder

Generert fra metodegrafen og vist som maskinforslåtte relasjoner – ingen bevispåstand er underforstått.